Inhibiting the STAT6 signaling pathway can diminish the population of M2-TAM and facilitate their reprogramming to the Mz1 phenotype, hence increasing the susceptibility of NSCLC to radiotherapy. The gene discussed is STAT6; the disease is non-small cell lung carcinoma.